                                 CODE OF VIRGINIA

SCHEDULE IV (§ 54.1-3452)

The controlled substances listed in this section are included in Schedule IV
unless specifically excepted or listed in another schedule:

1. Any material, compound, mixture, or preparation which contains any quantity
of the following substances having a potential for abuse associated with a
depressant effect on the central nervous system:
			Alfaxalone (5[alpha]-pregnan-3[alpha]-ol-11,20-dione), previously spelled
&#8220;alphaxalone,&#8221; including its salts, isomers, and salts of isomers;
			Alprazolam;
			Barbital;
			Brexanolone;
			Bromazepam;
			Camazepam;
			Carisoprodol;
			Chloral betaine;
			Chloral hydrate;
			Chlordiazepoxide;
			Clobazam;
			Clonazepam;
			Clorazepate;
			Clotiazepam;
			Cloxazolam;
			Daridorexant;
			Delorazepam;
			Diazepam;
			Dichloralphenazone;
			Estazolam;
			Ethchlorvynol;
			Ethinamate;
			Ethyl loflazepate;
			Fludiazepam;
			Flunitrazepam;
			Flurazepam;
			Fospropofol;
			Halazepam;
			Haloxazolam;
			Ketazolam;
			Lemborexant;
			Loprazolam;
			Lorazepam;
			Lormetazepam;
			Mebutamate;
			Medazepam;
			Methohexital;
			Meprobamate;
			Methylphenobarbital;
			Midazolam;
			Nimetazepam;
			Nitrazepam;
			Nordiazepam;
			Oxazepam;
			Oxazolam;
			Paraldehyde;
			Petrichloral;
			Phenobarbital;
			Pinazepam;
			Prazepam;
			Quazepam;
			Remimazolam;
			Suvorexant
([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-
(2H-1, 2, 3-triazol-2-yl)phenyl]methanone), including its salts, isomers, and
salts of isomers;
			Temazepam;
			Tetrazepam;
			Triazolam;
			Zaleplon;
			Zolpidem;
			Zopiclone;
			Zuranolone.

2. Any compound, mixture or preparation which contains any quantity of the
following substances including any salts or isomers thereof:
			Lorcaserin.

3. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers (whether optical, position, or geometric), and
salts of such isomers whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:
			Cathine (+)-norpseudoephedrine;
			Diethylpropion;
			Fencamfamin;
			Fenproprex;
			Mazindol;
			Mefenorex;
			Modafinil;
			Phentermine;
			Pemoline (including organometallic complexes and chelates thereof);
			Pipradrol;
			Serdexmethylphenidate;
			Sibutramine;
			Solriamfetol (2-amino-3-phenylpropyl carbamate);
			SPA (-)-1-dimethylamino-1,2-diphenylethane.

4. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation containing any of the following
narcotic drugs, or their salts calculated as the free anhydrous base or
alkaloid, in limited quantities as set forth below:
			Dextropropoxyphene
(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
			Not more than 1 milligram of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit;
			2-[(dimethylamino) methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts,
optical and geometric isomers, and salts of such isomers, including tramadol.

5. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances, including their salts:
			Butorphanol (including its optical isomers);
			Eluxadoline (including its optical isomers and its salts, isomers, and salts
of isomers);
			Pentazocine.

6. The Board may except by regulation any compound, mixture, or preparation
containing any depressant substance listed in subdivision 1 from the application
of all or any part of this chapter if the compound, mixture, or preparation
contains one or more active medicinal ingredients not having a depressant effect
on the central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the potential
for abuse of the substances which have a depressant effect on the central
nervous system.

HISTORY: 1972, c. 798, § 54-524.84:10; 1976, c. 614; 1977, c. 302; 1978, c.
705; 1979, c. 387; 1982, c. 505; 1986, c. 463; 1988, cc. 283, 765; 1992, c. 737;
1994, c. 763; 1998, c. 105; 1999, c. 605; 2000, c. 135; 2003, c. 640; 2006, c.
346; 2010, c. 423; 2012, c. 540; 2014, c. 74; 2015, c. 303; 2016, c. 499; 2022,
cc. 114, 115; 2024, cc. 62, 228; 2025, c. 118.